Catalyst Calendar
Scope

Wed, Jul 8, 2026

1 updates
BLRX
7:00 AM

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose GLIX1 in combination with olaparib also showed comparable efficacy to that

biolinerx.com

Wed, May 27, 2026

1 updates
BLRX
7:00 AM

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model - -

Trial Start • Phase 1Trial initiation Sun, Mar 1, 2026biolinerx.com

Fri, May 22, 2026

1 updates

Wed, May 20, 2026

1 updates
BLRX
7:00 AM

BioLineRx to Report First Quarter 2026 Results on May 27, 2026

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its

biolinerx.com

Tue, May 19, 2026

1 updates
BLRX
7:00 AM

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts

New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested Results highlight GLIX1's potential to address the high unmet need for patients with GBM TEL AVIV, Israel and OSLO, Norway, May 19,

biolinerx.com

Tue, Apr 28, 2026

1 updates